Amgen Inc (AMGN)

174.06
1.90 1.10
NASDAQ : Health Care
Prev Close 172.15
Open 172.00
Day Low/High 171.71 / 173.94
52 Wk Low/High 130.09 / 181.81
Volume 1.27M
Avg Volume 3.37M
Exchange NASDAQ
Shares Outstanding 731.00M
Market Cap 128.58B
EPS 10.30
P/E Ratio 16.02
Div & Yield 4.60 (2.60%)

Latest News

Stock Futures Rise on Earnings Beats From AMD and Boeing

Stock Futures Rise on Earnings Beats From AMD and Boeing

Stock futures are higher.

The Dow Binges on Earnings

The Dow Binges on Earnings

Get ready for another heavy earnings slate

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

U.S. stock futures turn higher on Tuesday following earnings from Alphabet.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

Intermediate Trade: QQQ

Intermediate Trade: QQQ

Try this bearishly biased, out-of-the-money put spread on the Nasdaq 100 ETF.

FDA Accepts Biologics License Application For Aimovig™ (erenumab)

FDA Accepts Biologics License Application For Aimovig™ (erenumab)

Aimovig is an Investigative Migraine-Specific Preventive Therapy Designed for Patients With High Unmet Need

Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation

Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation

Array to Advance Preclinical Program for Autoimmune Disorders

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label

Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)

Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)

First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee

Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma

Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma

KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone

FDA Grants Full Approval For BLINCYTO® (blinatumomab) To Treat Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia In Adults And Children

FDA Grants Full Approval For BLINCYTO® (blinatumomab) To Treat Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia In Adults And Children

BLINCYTO is the First-and-Only Bispecific T Cell Engager (BiTE®) Immunotherapy to Demonstrate Superior Overall Survival Versus Standard of Care Chemotherapy

Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket

Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket

Two Diagnostic Companies Will Receive Lab Space and Other Benefits at San Francisco Life Sciences Incubator

First Witness to Testify in Pharma Bro's Trial Felt 'Betrayed'

First Witness to Testify in Pharma Bro's Trial Felt 'Betrayed'

Sarah Hassan, daughter of pharmaceutical executive Fred Hassan, was ignored by Shkreli for nearly a year before she received returns on her original investment.

Another Steep Selloff in Tech Stocks Wipes Out Nasdaq's June Gains

Another Steep Selloff in Tech Stocks Wipes Out Nasdaq's June Gains

A tech selloff yields big Wall Street losses.

FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer

FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer

Vectibix Demonstrated an Improvement in Overall Survival in Patients With Wild-Type RAS Metastatic Colorectal Cancer

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Stocks Lower as Tech Losses Escalate, Senate Delays Its Healthcare Plan

Tech, healthcare slide weighs on rest of markets.

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Senate Punts Vote on Healthcare Bill, Wall Street Fares Poorly

Healthcare's slide weighs on rest of markets.

How President Trump Has Sent Biotech Stocks Soaring

How President Trump Has Sent Biotech Stocks Soaring

The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.

Biotech Movers: Regeneron Slides Back After Big Gains

Biotech Movers: Regeneron Slides Back After Big Gains

The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Amgen Defends Drug Pipeline, Says the Best is Yet to Come

Amgen Defends Drug Pipeline, Says the Best is Yet to Come

Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.

Amgen To Present New Data At 22nd Congress Of The European Hematology Association

Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma